STRO-227 / Sutro Biopharma - LARVOL DELTA

Preclinical characterization of STRO-227: A PTK7-targeting dual-payload ADC with topoisomerase 1 and tubulin inhibitors (AACR 2026) - "In multiple xenograft and patient-derived xenograft (PDX) models, STRO-227 exhibited superior anti-tumor activity compared to the corresponding single-payload ADCs. In addition, STRO-227 demonstrated a favorable safety and pharmacokinetic profile in non-human primates, with a highest non-severely toxic dose (HNSTD) comparable to established MMAE- and topoisomerase I-based single-payload ADC benchmarks."

ADC • Preclinical • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PTK7

Select Poster Highlights:…Preclinical data for STRO-227 (GlobeNewswire) - "...Demonstrated robust, dose-dependent antitumor activity across multiple solid tumor models, including breast, ovarian and NSCLC, with improved efficacy versus single-payload ADCs. The program also shows favorable pharmacokinetics, stable payload delivery, and tolerability comparable to benchmark ADCs, supporting the potential of its dual-payload design. These findings position STRO-227 as a differentiated ADC with broad applicability across solid tumors. Sutro expects to file an IND for STRO-227, its first wholly-owned dual-payload ADC, in late 2026."

IND • Preclinical • Breast Cancer • Non Small Cell Lung Cancer • Ovarian Cancer

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day (GlobeNewswire) - "The presentation will include an overview of Sutro’s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The Company will also provide details on its dual-payload ADC programs, uniquely enabled by its proprietary cell-free platform, and reveal STRO-227, its first dual-payload candidate designed to target PTK7."

Clinical • New molecule • Solid Tumor